Provided by Tiger Trade Technology Pte. Ltd.

Lakefront Biotherapeutics

28.55
+0.05000.18%
Post-market: 28.550.00000.00%18:23 EDT
Volume:149.04K
Turnover:4.25M
Market Cap:1.88B
PE:2.77
High:28.67
Open:28.41
Low:28.35
Close:28.50
52wk High:37.78
52wk Low:25.68
Shares:65.90M
Float Shares:23.98M
Volume Ratio:0.79
T/O Rate:0.62%
Dividend:- -
Dividend Rate:- -
EPS(TTM):10.31
EPS(LYR):5.72
ROE:20.12%
ROA:9.93%
PB:0.50
PE(LYR):4.99

Loading ...

Analysts Conflicted on These Healthcare Names: Alnylam Pharma (ALNY), Lakefront Biotherapeutics (LKFT) and BioNTech SE (BNTX)

TIPRANKS
·
Aug 31

Lakefront Biotherapeutics Autoimmune Disorder Pemphigus Treatment Gets FDA Orphan Drug Designation

Dow Jones
·
Aug 25

Lakefront Biotherapeutics granted orphan drug designation for gamgertamig

TIPRANKS
·
Aug 25

Lakefront Biotherapeutics Nv : TD Cowen Reinstates Coverage with Buy Rating

THOMSON REUTERS
·
Aug 21

Lakefront Biotherapeutics is Maintained at Sector Perform by RBC Capital

Dow Jones
·
Aug 11

RBC Adjusts PT on Lakefront Biotherapeutics to $26 From $28, Keeps Sector Perform Rating

MT Newswires Live
·
Aug 11

Morgan Stanley Adjusts PT on Lakefront Biotherapeutics to $26 From $30, Maintains Equalweight Rating

MT Newswires Live
·
Aug 11

Lakefront Biotherapeutics NV Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 11

Lakefront Biotherapeutics Q2 EPS $0.29 Beats $(13.52) Estimate, Sales $21.624M Beat $7.210M Estimate

Benzinga Earnings
·
Aug 11

Lakefront Biotherapeutics NV Expected to Post a Loss of €4.64 a Share - Earnings Preview

Reuters
·
Aug 08

Earning Preview: Lakefront Biotherapeutics this quarter’s revenue is expected to decrease by 88.74%, and institutional views are constructive

Earnings Agent
·
Aug 03

Lakefront Biotherapeutics resumed with an Equal Weight at Morgan Stanley

TIPRANKS
·
Jul 10

Judah Frommer Maintains Hold on LKFT, Citing Early but Strategic Gamgertamig Acquisition and Limited Economic Upside

TIPRANKS
·
Jul 10

Lakefront Biotherapeutics Launches 50 Million Euros Share Repurchase Program

MT Newswires Live
·
Jun 10

Lakefront Biotherapeutics announces EUR 50M share repurchase program

TIPRANKS
·
Jun 10

Lakefront Biotherapeutics Names Eric Hedrick as Chief Medical Officer

MT Newswires Live
·
Jun 09

Dermatomyositis Trial Update Sets Context For LKFT’s Autoimmune Pipeline

TIPRANKS
·
May 15

Lakefront Biotherapeutics Spotlight: Completed Phase 2 Lupus Study Sets Stage for Key Data Catalyst

TIPRANKS
·
May 15

Two new option listings and five option delistings on May 8th

TIPRANKS
·
May 09

Galapagos NV reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 07